![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: TATDN1 |
Gene summary for TATDN1 |
![]() |
Gene information | Species | Human | Gene symbol | TATDN1 | Gene ID | 83940 |
Gene name | TatD DNase domain containing 1 | |
Gene Alias | CDA11 | |
Cytomap | 8q24.13 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q6P1N9 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
83940 | TATDN1 | LZE4T | Human | Esophagus | ESCC | 1.74e-20 | 6.65e-01 | 0.0811 |
83940 | TATDN1 | LZE7T | Human | Esophagus | ESCC | 7.87e-07 | 5.91e-01 | 0.0667 |
83940 | TATDN1 | LZE8T | Human | Esophagus | ESCC | 1.63e-02 | 2.08e-01 | 0.067 |
83940 | TATDN1 | LZE20T | Human | Esophagus | ESCC | 3.69e-08 | 4.99e-01 | 0.0662 |
83940 | TATDN1 | LZE22D1 | Human | Esophagus | HGIN | 1.46e-02 | 1.15e-01 | 0.0595 |
83940 | TATDN1 | LZE24T | Human | Esophagus | ESCC | 4.14e-23 | 7.93e-01 | 0.0596 |
83940 | TATDN1 | LZE6T | Human | Esophagus | ESCC | 1.32e-04 | 3.06e-01 | 0.0845 |
83940 | TATDN1 | P1T-E | Human | Esophagus | ESCC | 2.71e-10 | 3.20e-01 | 0.0875 |
83940 | TATDN1 | P2T-E | Human | Esophagus | ESCC | 2.04e-24 | 4.54e-01 | 0.1177 |
83940 | TATDN1 | P4T-E | Human | Esophagus | ESCC | 5.90e-30 | 9.14e-01 | 0.1323 |
83940 | TATDN1 | P5T-E | Human | Esophagus | ESCC | 9.53e-41 | 9.31e-01 | 0.1327 |
83940 | TATDN1 | P8T-E | Human | Esophagus | ESCC | 4.06e-21 | 3.05e-01 | 0.0889 |
83940 | TATDN1 | P9T-E | Human | Esophagus | ESCC | 6.83e-23 | 6.37e-01 | 0.1131 |
83940 | TATDN1 | P10T-E | Human | Esophagus | ESCC | 2.68e-29 | 6.15e-01 | 0.116 |
83940 | TATDN1 | P11T-E | Human | Esophagus | ESCC | 1.13e-16 | 5.78e-01 | 0.1426 |
83940 | TATDN1 | P12T-E | Human | Esophagus | ESCC | 4.70e-41 | 8.48e-01 | 0.1122 |
83940 | TATDN1 | P15T-E | Human | Esophagus | ESCC | 5.81e-41 | 9.99e-01 | 0.1149 |
83940 | TATDN1 | P16T-E | Human | Esophagus | ESCC | 1.54e-43 | 9.26e-01 | 0.1153 |
83940 | TATDN1 | P17T-E | Human | Esophagus | ESCC | 3.02e-12 | 6.33e-01 | 0.1278 |
83940 | TATDN1 | P19T-E | Human | Esophagus | ESCC | 6.16e-09 | 1.02e+00 | 0.1662 |
Page: 1 2 3 4 5 6 7 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Esophagus | ESCC | ![]() |
Skin | AK | ![]() |
Skin | SCCIS | ![]() |
Skin | cSCC | ![]() |
Thyroid | HT | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00903053 | Esophagus | ESCC | nucleic acid phosphodiester bond hydrolysis | 163/8552 | 261/18723 | 3.07e-08 | 5.73e-07 | 163 |
GO:0090305 | Liver | HCC | nucleic acid phosphodiester bond hydrolysis | 152/7958 | 261/18723 | 1.90e-07 | 3.46e-06 | 152 |
GO:00903052 | Oral cavity | OSCC | nucleic acid phosphodiester bond hydrolysis | 142/7305 | 261/18723 | 2.90e-07 | 4.43e-06 | 142 |
GO:00903051 | Oral cavity | LP | nucleic acid phosphodiester bond hydrolysis | 92/4623 | 261/18723 | 8.07e-05 | 1.04e-03 | 92 |
GO:00903054 | Skin | cSCC | nucleic acid phosphodiester bond hydrolysis | 97/4864 | 261/18723 | 4.08e-05 | 4.34e-04 | 97 |
GO:00903055 | Thyroid | PTC | nucleic acid phosphodiester bond hydrolysis | 105/5968 | 261/18723 | 2.53e-03 | 1.31e-02 | 105 |
GO:009030511 | Thyroid | ATC | nucleic acid phosphodiester bond hydrolysis | 107/6293 | 261/18723 | 7.21e-03 | 2.84e-02 | 107 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TATDN1 | SNV | Missense_Mutation | c.694N>T | p.His232Tyr | p.H232Y | Q6P1N9 | protein_coding | deleterious(0) | possibly_damaging(0.825) | TCGA-AN-A0FY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
TATDN1 | SNV | Missense_Mutation | c.599N>C | p.Leu200Pro | p.L200P | Q6P1N9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
TATDN1 | SNV | Missense_Mutation | novel | c.239N>C | p.Arg80Thr | p.R80T | Q6P1N9 | protein_coding | deleterious(0) | possibly_damaging(0.721) | TCGA-C5-A3HD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
TATDN1 | SNV | Missense_Mutation | c.21N>G | p.Ile7Met | p.I7M | Q6P1N9 | protein_coding | deleterious(0) | benign(0.275) | TCGA-IR-A3LL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
TATDN1 | SNV | Missense_Mutation | c.644N>C | p.Glu215Ala | p.E215A | Q6P1N9 | protein_coding | deleterious(0.03) | possibly_damaging(0.455) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
TATDN1 | SNV | Missense_Mutation | rs771415518 | c.452N>A | p.Arg151Gln | p.R151Q | Q6P1N9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TATDN1 | SNV | Missense_Mutation | novel | c.241T>C | p.Cys81Arg | p.C81R | Q6P1N9 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TATDN1 | SNV | Missense_Mutation | c.282N>T | p.Lys94Asn | p.K94N | Q6P1N9 | protein_coding | tolerated(0.58) | benign(0) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TATDN1 | SNV | Missense_Mutation | novel | c.551C>T | p.Ala184Val | p.A184V | Q6P1N9 | protein_coding | tolerated(0.28) | benign(0.062) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TATDN1 | SNV | Missense_Mutation | novel | c.508G>T | p.Gly170Trp | p.G170W | Q6P1N9 | protein_coding | deleterious(0.02) | probably_damaging(0.997) | TCGA-AX-A3FT-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |